Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
87 /100
COMPONENT-LIMITED
Score updated Aug 28, 2026

DRMA — Dermata Therapeutics, Inc. Dilution Risk Tracker

Track DRMA dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track DRMA — Get alerts when the score changes →

As of August 28, 2026, Dermata Therapeutics, Inc. (DRMA) has a DilutionWatch DilutionScore of 87/100, rated CRITICAL dilution risk. This is a component-limited score because one or more material inputs are unavailable or not applicable. Dermata Therapeutics, Inc. has a market capitalization of $5.23M, 4.02M shares outstanding, 2 institutional holders tracked. Stored dilution-related fields include 5.42M outstanding warrants.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
80
💰 Cash Runway
65
📊 Float Risk
42
⚠️ Warrant Exposure
90
🔄 Convertible Debt
85

Dilution Forecast

⛈️
Warning
High probability of dilution event
model est. 56%
📜 Warrant Exercise model 60%
• Massive warrant overhang: 135% of shares outstanding
• Warrant risk score very high (90/100)
🔁 Convertible Conversion model 60%
• Major convertible overhang: 49% potential dilution
• Convertible risk score very high (85/100)
🔄 Reverse Split model est. 40%
• 50-day avg $1.28 approaching $1 threshold
• 6 months cash with weak price
🔔 Track DRMA — Get forecast alerts →

Market Data

Market Cap$5.23M
Shares Outstanding4.02M
Float3.17M
Cash$4.41M
DebtN/A
Short InterestN/A

Institutional Holdings

2 institutional holders · 89.9K shares
#1 MORGAN STANLEY 89.8K shares
#2 BARCLAYS PLC 180 shares

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest50.8K
Days to Cover1.0
% of Float1.6%
FINRA data as of Jul 31, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2026-06-30
xbrl XBRL CONVERTIBLE 2022-12-31
Full SEC filing analysis available with free account

Recent News

No recent news

Factual DRMA Dilution Snapshot

Dermata Therapeutics, Inc. (DRMA) has a DilutionScore of 87/100, rated Critical dilution risk. Score date: August 28, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

Track DRMA Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking DRMA — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — CRITICAL Risk

Other CRITICAL dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,024+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations

Score Coverage Note

More Research for DRMA
DRMA FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.